The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) differs
from that of the primary tumor and is dynamic during tumor progression. The real-time and …

Purpose To evaluate the prognostic significance of circulating tumour cell (CTC) number
determined on the Epic Sciences platform in men with metastatic castration-resistant …

Purpose: PARP inhibitors (PARPi) are efficacious in multiple cancers harboring germline
(and possibly somatic) BRCA1/2 mutations. Acquired reversions can restore BRCA1/2 …

In the era of precision oncology, liquid biopsy techniques, especially the use of plasma
circulating tumour DNA (ctDNA) analysis, represent a paradigm shift in the use of genomic …

Background There is a lack of molecularly-informed biomarkers for patients with metastatic
renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally …

Abstract Background Prostate cancer (PCa) shows racial disparity in clinical and genomic
characteristics, and Asian patients with PCa often present with more aggressive phenotypes …

Deleterious aberrations in DNA repair genes are actionable in approximately 25% of
metastatic castration-resistant prostate cancers (mCRPC) patients. Homology recombination …

Bladder cancer (BC) is among the most common malignant tumors of the genitourinary
system worldwide. In recent years, the rate of BC incidence has increased, and the …

Objectives To investigate the genetic alterations of patients with prostate cancer (PCa) with
and without intraductal carcinoma of the prostate (IDC‐P). Patients and Methods We …

Enzalutamide, an antiandrogen, is approved for therapy of castration resistant prostate
cancer. Clinical applications have shown that approximately 30% of patients acquire …